Search

Your search keyword '"DE MARINIS, F."' showing total 1,084 results

Search Constraints

Start Over You searched for: Author "DE MARINIS, F." Remove constraint Author: "DE MARINIS, F."
1,084 results on '"DE MARINIS, F."'

Search Results

303. Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)

305. Paramount: Descriptive Subgroup Analyses of Final Overall Survival (OS) for the Phase III Study of Maintenance Pemetrexed (PEM) Versus Placebo (PLB) Following Induction Treatment with PEM Plus Cisplatin (CIS) for Advanced Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC)

306. Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study

309. 9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results

310. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study

311. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).

312. Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials.

313. Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC).

314. PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non–small cell lung cancer (NSCLC).

317. 4IN ESMO RECOMMENDATION 2011: ADVANCED NSCLC

319. First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: Efficacy by histology.

323. 9034 Medical treatment choices of over 1000 Italian patients affected by stage IIIB-IV NSCLC in routine clinical practice: results from the observational "SUN" (Survey on the lUng cancer maNagement) study on behalf of SUN study Group

324. 9161 FLEX study: Prognostic factors in NSCLC

326. Corrigendum to “Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting” [Crit. Rev. Oncol./Hematol. 66 (2008) 155–162]

331. Activity and tolerability of Cisplatin (CDDP) and Fotemustine (FTM) combination in the treatment of patients with non-small cell lung cancer (NSCLC) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)

336. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting

340. Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer

341. A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy

344. Treatment of advanced non-small cell lung cancer

350. P-463 Preliminary results of a multicenter randomized phase II trial oftwo different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non small cell lung cancer (NSCLC)

Catalog

Books, media, physical & digital resources